Continuous administration of recombinant human endostatin (Endostar): A pre-clinical safety study

Huang,Ruofan; Zhan,Qiong; Zhou,Xinli; Chu,Zhaohui; Jiang,Jingwei; Liang,Xiaohua

doi:10.3892/etm.2012.534

June 2012 Volume 3 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June 2012 Volume 3 Issue 6

Full Size Image

Article

Continuous administration of recombinant human endostatin (Endostar): A pre-clinical safety study

Authors:
- Ruofan Huang
- Qiong Zhan
- Xinli Zhou
- Zhaohui Chu
- Jingwei Jiang
- Xiaohua Liang
View Affiliations / Copyright

Affiliations: Department of Oncology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Pages: 1018-1022
|
Published online on: March 30, 2012

https://doi.org/10.3892/etm.2012.534
Expand metrics +

Abstract

The aim of this study was to evaluate the safety of the continuous administration of recombinant human endostatin (Endostar) in healthy mice. A total of 16 nude mice were randomly divided into four treatment groups: a continuous administration group injected intraperitoneally (i.p.) with 14 mg/kg Endostar over seven days, an intermittent administration group injected i.p. with 2 mg/kg Endostar daily for seven days, a saline injection group and an untreated control group. All mice were implanted with an intraperitoneal mini-osmotic drug pump filled with Endostar or saline. The serum concentration of Endostar, the cell fraction of CD11b-CD146+CD105+ vascular endothelial cells in the peripheral blood, the injury of the myocardial, lung and kidney tissues and the density of microvessels within these organs were observed 24 h after the termination of drug or saline administration. Only trace amounts of Endostar were detected in the serum of the continuous administration and intermittent administration groups. Myocardial, lung and kidney tissues exhibited no detectable signs of injury and no differences in the density of microvessels were found in these organs among the four groups. Yet, the cell fraction (in %) of CD11b-CD146+CD105+ vascular endothelial cells in the peripheral blood was higher in the continuous administration group compared with that in the other treatment groups (P=0.011). This suggests that intermittent Endostar delivery did not significantly impact the vascular endothelium, while continuous Endostar administration may promote injury of the endothelium. In conclusion, the continuous administration of Endostar does not appear to be a safe method by which to administer this antiangiogenic agent to healthy nude mice.

View Figures

View References

1.	Jiang LP, Zou C, Yuan X, Luo W, Wen Y and Chen Y: N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol Appl Biochem. 54:113–120. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Han B, Xiu Q, Wang H, Shen J, Gu A and Luo Y: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol. 6:1104–1109. 2011. View Article : Google Scholar
3.	Paborsky LR, Dunn KE, Gibbs CS and Dougherty JP: A nickel chelate microtiter plate assay for six histidine-containing proteins. Anal Biochem. 234:60–65. 1996. View Article : Google Scholar : PubMed/NCBI
4.	Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlation with metastasis in invasive prostate carcinoma. Am J Pathol. 143:401–409. 1993.
5.	Shaked Y, Henke E, Roodhart JM, et al: Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 14:263–273. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Celik I, Surucu O, Dietz C, et al: Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 65:11044–11050. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Despoix N, Walzer T, Jouve N, et al: Mouse CD146/MCAM is a marker of natural killer cell maturation. Eur J Immunol. 38:2855–2864. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Dallas NA, Samuel S, Xia L, et al: Endoglin (CD105): A marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 14:19312008. View Article : Google Scholar : PubMed/NCBI
9.	Khan SS, Solomon MA and McCoy JP Jr: Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom. 64:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Abdelmoneim SS, Talwalkar J, Sethi S, Kamath P, et al: A prospective pilot study of circulating endothelial cells as a potential new biomarker in portal hypertension. Liver Int. 30:191–197. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Goon PK, Boos CJ and Lip GY: Circulating endothelial cells: markers of vascular dysfunction. Clin Lab. 51:531–538. 2005.PubMed/NCBI
12.	Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, et al: Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. Crit Rev Oncol Hematol. 69:108–124. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Erdbruegger U, Haubitz M and Woywodt A: Circulating endothelial cells: A novel marker of endothelial damage. Clin Chim Acta. 373:17–26. 2006. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Continuous administration of recombinant human endostatin (Endostar): A pre-clinical safety study

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles